Drug class: GLP-1/Amylin receptor dual agonist Route: Once-weekly subcutaneous injection AND once-daily oral tablet Developer: Novo Nordisk Phase: Phase 3 (AMAZE program obesity
Funding This work was supported by a Steno Collaborative Grant, Novo Nordisk Foundation, Denmark (Grant no
AGEs can be taken exogenously, through the consumption of food and smoke, or produced endogenously
Cgnz1 allele confers kidney resistance to damage preventing progression of immune complex-mediated acute lupus glomerulonephritis
The GLP-1 High Protein Cookbook for Weight Loss: Easy, Satisfying Recipes & a 60-Day Meal Plan to Reduce Hunger, Boost Energy, and Build Consistency Without Restriction - Kindle edition by Jacobs, Willow
Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C(10))